drugset / Trial / NCT01000922

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

NCT01000922

Phase 2 Completed 24 enrolled Biodel
Non-randomizedCrossoverOpen-labelTreatment

Summary

Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.

Timeline

Start
2006-06
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Subcutaneous
Subject Insulin Lispro Protein / enzyme biologic Subcutaneous
Subject VIAject™ Protein / enzyme biologic 50 % Subcutaneous
Background insulin glargine Protein / enzyme biologic Subcutaneous

Indications